After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Cullinan Therapeutics Inc is $488.56M. A total of 0.65 million shares were traded on the day, compared to an average of 899.83K shares.
In the most recent transaction, Lynx1 Capital Management LP bought 165,667 shares of CGEM for 8.40 per share on Oct 28 ’25. After the transaction, the 10% Owner now owns 8,963,500 company shares. In a previous transaction on Oct 16 ’25, Lynx1 Capital Management LP bought 150,000 shares at 8.86 per share. CGEM shares that 10% Owner owns now total 8,765,616.
Among the insiders who bought shares, Lynx1 Capital Management LP acquired of 51,500 shares on Oct 15 ’25 at a per-share price of $7.94. This resulted in the 10% Owner holding 8,615,616 shares of CGEM after the transaction. In another insider transaction, Lynx1 Capital Management LP bought 32,217 shares at $7.84 per share on Oct 17 ’25. Company shares held by the 10% Owner now total 8,797,833.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, CGEM has a high of $16.45 and a low of $5.68.
As of this writing, CGEM has an earnings estimate of -$0.86 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.77 per share and a lower estimate of -$0.99. The company reported an EPS of -$0.73 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CGEM’s latest balance sheet shows that the firm has $290.47M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $11.75M in liabilities at the time. Its Book Value Per Share was $7.64, while its Total Shareholder’s Equity was $425.37M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CGEM is Buy with a score of 4.82.
